9. STOCK-BASED COMPENSATION

Employee equity plans

In March 2020, the Company’s board of directors and stockholders approved the 2020 Stock Option and Grant Plan (“2020 Plan”). Holders of stock options under the 2020 Plan are entitled to exercise the vested portion of the stock option during the term of the grant. No further equity awards will be granted under the 2020 Plan. Effective as of the Redomestication, the Company's board of directors approved an amendment and restatement of the 2020 Plan to reflect the conversion of Common Stock into Ordinary Shares in connection with the Redomestication.

In October 2020, the Company’s board of directors and stockholders approved the 2020 Equity Incentive Plan (“2020 Equity Plan”). Following the adoption of the 2020 Equity Plan, no further equity awards were issued under the 2020 Plan. Stock-based awards granted under the 2020 Equity Plan generally vest over a four-year period and expire ten years from the grant date. No further equity awards will be granted under the 2020 Equity Plan. Effective as of the Redomestication, the Company's board of directors approved an amendment and restatement of the 2020 Equity Plan to reflect the conversion of Common Stock into Ordinary Shares in connection with the Redomestication.

In November 2022, the Company’s board of directors approved the 2022 Inducement Plan (the “Inducement Plan”), which allows for the grant of equity awards to be made to new employees where the equity award is a material inducement to an employee entering into employment with the Company. The Inducement Plan was adopted by the Company’s board of directors without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4). In December 2025, the Company’s board of directors approved an increase of 7,990,000 shares of Common Stock reserved for issuance under the Inducement Plan. At June 30, 2026, the Company had 3,602,447 shares available for future grant under the Inducement Plan. During the six months ended June 30, 2026, 3,130,013 options were granted under the Inducement Plan at a weighted average exercise price of $24.43. The weighted average remaining contractual terms for these options is 10 years. No equity grants were issued under the Inducement Plan during the six months ended June 30, 2025. Effective as of the Redomestication, the Company's board of directors approved an amendment and restatement of the Inducement Plan to reflect the conversion of Common Stock into Ordinary Shares in connection with the Redomestication.

The Damora Therapeutics, Inc. 2025 Equity Incentive Plan (“2025 Plan”) was adopted by the board of directors of Pre-Acquisition Damora on August 22, 2025. The 2025 Plan provided for Pre-Acquisition Damora to grant stock options, restricted stock awards, restricted stock units, and other stock-based awards to employees, officers, directors, consultants, and advisors. Stock options and restricted stock awards granted under the 2025 Plan generally vest over four years, subject to the participant’s continued service. As of June 30, 2026, there were options to purchase 434,508 shares of Common Stock and 250,725 shares of Restricted Common Stock outstanding under the 2025 Plan. No further equity awards will be granted under the 2025 Plan. Effective as of the Redomestication, the Company's board of directors approved an amendment and restatement of the 2025 Plan to reflect the conversion of Common Stock into Ordinary Shares in connection with the Redomestication.

In February 2026, the Company’s stockholders approved the 2026 Equity Incentive Plan (“2026 Equity Plan”). Following the adoption of the 2026 Equity Plan, no further equity awards will be issued under the 2020 Equity Plan. The initial share pool under the 2026 Equity Plan was 9,299,832 shares of Common Stock, subject to certain adjustments in the event of a change in the Company’s capitalization. Stock-based awards granted under the 2026 Equity Plan generally vest over a four-year period and expire ten years from the grant date. Shares available for grant under the 2026 Equity Plan cumulatively increase by 5% of the number of shares of Common Stock issued and outstanding on January 1st each year until 2035. At June 30, 2026, the Company had 8,705,367 shares available for future grant under the 2026 Equity Plan. Effective as of the Redomestication, the Company's board of directors approved an amendment and restatement of the 2026 Equity Plan to reflect the conversion of Common Stock into Ordinary Shares in connection with the Redomestication.

In February 2026, the Company's stockholder adopted the 2026 Employee Stock Purchase Plan (the “2026 ESPP”). The number of shares of our Common Stock reserved for issuance under the 2026 ESPP is equal to 619,989 subject to an annual increase, to be

added on the first day of each fiscal year, beginning January 1, 2027, equal to the lesser of (1) 1% of the number of shares of Common Stock outstanding on the first day of such fiscal year; (2) 1,000,000 shares of our Common Stock; or (3) such other amount as determined by our board of directors. As of June 30, 2026, the Company had not issued any shares under the 2026 ESPP. Effective as of the Redomestication, the Company's board of directors approved an amendment and restatement of the 2026 ESPP to reflect the conversion of Common Stock into Ordinary Shares in connection with the Redomestication.

The weighted-average grant date fair value of all stock options granted during the six months ended June 30, 2026 was $17.38. The intrinsic value at June 30, 2026 and December 31, 2025 is based on the closing price of the Common Stock on that date of $26.01 and $23.01 per share, respectively.

The Company uses a Black-Scholes option pricing model to determine fair value of its stock options. The Black-Scholes option pricing model includes various assumptions, including the fair value of common shares, expected life of stock options, the expected volatility based on the historical volatility of a publicly traded set of peer companies and the expected risk-free interest rate based on the implied yield on a U.S. Treasury security. The fair value of each option was estimated on the date of grant using the assumptions in the table below:

Paramora warrant obligation

On November 10, 2025, in connection with the Asset Acquisition, the Company assumed the Paramora Warrant Obligation which provided for an annual equity grant of warrants for Paramora to purchase 1% of the then outstanding shares of Common Stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Paragon Option Agreement, at the fair market value determined by the board of directors of the Company. The Company determined that the 2025 and 2026 grants are two separate grants, as there would be no obligation for the 2026 grant had the Company exercised or terminated all of the options under the Paragon Option Agreement prior to December 31, 2026. The service inception period for the grant precedes the grant date, with the full award being vested as of the grant date with no post-grant date service requirement.

As of June 30, 2026, the estimated fair value of the warrants to be granted on December 31, 2026, was approximately $19.2 million. For the six months ended June 30, 2026, $9.5 million was recognized as stock compensation expense related to the amortized expense of the Paramora Warrant Obligation. There was no similar expense for the six months ended June 30, 2025. As of June 30, 2026, the pro-rated unamortized expense related to the Paramora Warrant Obligation was $9.7 million.

The Company settled its 2025 obligations under the Paramora Warrant Obligation by issuing Paramora warrants to purchase 628,302 shares of Common Stock with an exercise price of $23.01 per share. As of June 30, 2026, none of the warrants issued under the Paramora Warrant Obligation have been exercised.

Restricted stock units

For the six months ended June 30, 2026, the Company granted 955,005 restricted stock units (“RSUs”) to its employees under the 2022 Inducement Plan. The weighted average grant date fair value of the time-based RSUs was $23.75 for the six months ended June 30, 2026. The RSUs vest 33% after one-year from the grant date and 17% every six-months thereafter, subject to continued service to the Company through the applicable vesting dates. For the three and six months ended June 30, 2026, the Company recognized $1.4 million and $2.1 million in expense related to the RSUs. For the three and six months ended June 30, 2025, the Company recognized a $23,000 and $46,000 expense related to the RSUs, respectively.

Stock-based compensation

The grant date fair value of stock awards vested during the six months ended June 30, 2026 and 2025 was $1.3 million and $417,000, respectively. Total unrecognized compensation expense related to unvested options granted under the Company’s stock-based compensation plan was $103.1 million at June 30, 2026, which is expected to be recognized over a weighted average period of 3.6 years. The Company recorded stock-based compensation expense related to the issuance of stock as follows (in thousands):